The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy
Diabetic neuropathy is one of the commonest complications of diabetes mellitus. Its most frequent form is diabetic peripheral neuropathy (DPN). Currently, there is no established and widely used biomarker for diagnosis and clinical staging of DPN. There is accumulating evidence that low-grade system...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Metabolism Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589936824000604 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850124255223611392 |
|---|---|
| author | Theodoros Panou Evanthia Gouveri Dimitrios Papazoglou Nikolaos Papanas |
| author_facet | Theodoros Panou Evanthia Gouveri Dimitrios Papazoglou Nikolaos Papanas |
| author_sort | Theodoros Panou |
| collection | DOAJ |
| description | Diabetic neuropathy is one of the commonest complications of diabetes mellitus. Its most frequent form is diabetic peripheral neuropathy (DPN). Currently, there is no established and widely used biomarker for diagnosis and clinical staging of DPN. There is accumulating evidence that low-grade systemic inflammation is a key element in its pathogenesis. In this context, several clinical studies have so far identified potential biomarkers of DPN. These studies have enrolled both subjects with type 1 diabetes mellitus (T1DM) and subjects with type 2 diabetes mellitus (T2DM), including children with T1DM and elderly T2DM subjects. They have also evaluated participants with prediabetes. Potential biomarkers include a wide spectrum of cytokines, chemokines and immune receptors, notably interleukins (IL), mostly IL-1, IL-6 or IL-10, as well as mediators of the tumour necrosis factor-α (TNF-α) related pathway. Cell-ratios, such as neurtrophil-to-lymphocyte ratio (NLR), have yielded promising results as well. Other works have focused on adipokines and identified several signalling molecules (adiponectin, neuregulin 4, isthmin-1 and omentin) as promising biomarkers of DPN. Finally, epigenetic biomarkers have been investigated. Further experience is being gathered with the use of biomarkers in specific age groups and in the discrimination between painless and painful DPN. Prospective studies appear promising in monitoring of DPN progression, but experience is rather limited. Finally, certain cut-off values have been proposed for DPN screening, but these need confirmation. Future large-scale studies are now required to validate biomarkers and to investigate their potential clinical utility. |
| format | Article |
| id | doaj-art-798552c830ec46babb82424a4dec4777 |
| institution | OA Journals |
| issn | 2589-9368 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Metabolism Open |
| spelling | doaj-art-798552c830ec46babb82424a4dec47772025-08-20T02:34:20ZengElsevierMetabolism Open2589-93682024-12-012410032810.1016/j.metop.2024.100328The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathyTheodoros Panou0Evanthia Gouveri1Dimitrios Papazoglou2Nikolaos Papanas3Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, GreeceDiabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, GreeceDiabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, GreeceCorresponding author.; Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, GreeceDiabetic neuropathy is one of the commonest complications of diabetes mellitus. Its most frequent form is diabetic peripheral neuropathy (DPN). Currently, there is no established and widely used biomarker for diagnosis and clinical staging of DPN. There is accumulating evidence that low-grade systemic inflammation is a key element in its pathogenesis. In this context, several clinical studies have so far identified potential biomarkers of DPN. These studies have enrolled both subjects with type 1 diabetes mellitus (T1DM) and subjects with type 2 diabetes mellitus (T2DM), including children with T1DM and elderly T2DM subjects. They have also evaluated participants with prediabetes. Potential biomarkers include a wide spectrum of cytokines, chemokines and immune receptors, notably interleukins (IL), mostly IL-1, IL-6 or IL-10, as well as mediators of the tumour necrosis factor-α (TNF-α) related pathway. Cell-ratios, such as neurtrophil-to-lymphocyte ratio (NLR), have yielded promising results as well. Other works have focused on adipokines and identified several signalling molecules (adiponectin, neuregulin 4, isthmin-1 and omentin) as promising biomarkers of DPN. Finally, epigenetic biomarkers have been investigated. Further experience is being gathered with the use of biomarkers in specific age groups and in the discrimination between painless and painful DPN. Prospective studies appear promising in monitoring of DPN progression, but experience is rather limited. Finally, certain cut-off values have been proposed for DPN screening, but these need confirmation. Future large-scale studies are now required to validate biomarkers and to investigate their potential clinical utility.http://www.sciencedirect.com/science/article/pii/S2589936824000604diabetic peripheral neuropathyType 1 diabetes mellitusType 2 diabetes mellitusInflammationDistal symmetrical polyneuropathyBiomarkers |
| spellingShingle | Theodoros Panou Evanthia Gouveri Dimitrios Papazoglou Nikolaos Papanas The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy Metabolism Open diabetic peripheral neuropathy Type 1 diabetes mellitus Type 2 diabetes mellitus Inflammation Distal symmetrical polyneuropathy Biomarkers |
| title | The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy |
| title_full | The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy |
| title_fullStr | The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy |
| title_full_unstemmed | The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy |
| title_short | The role of novel inflammation-associated biomarkers in diabetic peripheral neuropathy |
| title_sort | role of novel inflammation associated biomarkers in diabetic peripheral neuropathy |
| topic | diabetic peripheral neuropathy Type 1 diabetes mellitus Type 2 diabetes mellitus Inflammation Distal symmetrical polyneuropathy Biomarkers |
| url | http://www.sciencedirect.com/science/article/pii/S2589936824000604 |
| work_keys_str_mv | AT theodorospanou theroleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy AT evanthiagouveri theroleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy AT dimitriospapazoglou theroleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy AT nikolaospapanas theroleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy AT theodorospanou roleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy AT evanthiagouveri roleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy AT dimitriospapazoglou roleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy AT nikolaospapanas roleofnovelinflammationassociatedbiomarkersindiabeticperipheralneuropathy |